STRATEC Competitors

SRBZF Stock

USD 72.96 0.00 0.00%

STRATEC Biomedical competes with NVIDIA, Apple, Alphabet, Microsoft, and Amazon; as well as few others. Analyzing STRATEC Biomedical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of STRATEC Biomedical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out STRATEC Biomedical Correlation with its peers.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of STRATEC Biomedical competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
72.96	72.96	72.96

Details

Intrinsic

Valuation

Low	Real	High
72.96	72.96	72.96

Details

Naive

Forecast

Low	Next	High
72.96	72.96	72.96

Details

Bollinger

Band Projection (param)

Lower	Middle Band	Upper
72.96	72.96	72.96

Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as STRATEC Biomedical. Your research has to be compared to or analyzed against STRATEC Biomedical's peers to derive any actionable benefits. When done correctly, STRATEC Biomedical's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in STRATEC Biomedical.

STRATEC Biomedical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between STRATEC Biomedical and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of STRATEC and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of STRATEC Biomedical does not affect the price movement of the other competitor.

	NVDA	AAPL	GOOG	MSFT	AMZN	BMYMP	META	AVGO
NVDA		-0.06	-0.2	0.59	0.55	-0.43	0.08	0.1	NVDA
AAPL	-0.06		0.91	-0.63	0.53	0.74	-0.62	0.59	AAPL
GOOG	-0.2	0.91		-0.82	0.39	0.87	-0.65	0.57	GOOG
MSFT	0.59	-0.63	-0.82		-0.07	-0.84	0.67	-0.24	MSFT
AMZN	0.55	0.53	0.39	-0.07		0.15	-0.51	0.28	AMZN
BMYMP	-0.43	0.74	0.87	-0.84	0.15		-0.48	0.29	BMYMP
META	0.08	-0.62	-0.65	0.67	-0.51	-0.48		-0.19	META
AVGO	0.1	0.59	0.57	-0.24	0.28	0.29	-0.19		AVGO
	NVDA	AAPL	GOOG	MSFT	AMZN	BMYMP	META	AVGO

High positive correlations

GOOG	+ 0.91	AAPL
BMYMP	+ 0.87	GOOG
BMYMP	+ 0.74	AAPL
META	+ 0.67	MSFT
MSFT	+ 0.59	NVDA
AVGO	+ 0.59	AAPL

High negative correlations

BMYMP	- 0.84	MSFT
MSFT	- 0.82	GOOG
META	- 0.65	GOOG
MSFT	- 0.63	AAPL
META	- 0.62	AAPL
META	- 0.51	AMZN

Risk-Adjusted Indicators

There is a big difference between STRATEC Pink Sheet performing well and STRATEC Biomedical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze STRATEC Biomedical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
NVDA	1.82	0.01	0.00	0.06	2.20	(1.94)	3.01	(3.81)	9.61
AAPL	0.74	0.06	0.05	0.11	0.90	(0.76)	1.97	(1.56)	5.76
GOOG	1.40	0.34	0.23	0.38	1.14	(1.64)	3.33	(2.27)	9.42
MSFT	0.89	(0.12)	0.00	(0.16)	0.00	0.00	1.78	(2.50)	5.08
AMZN	1.38	0.00	0.01	0.05	1.87	(1.27)	2.53	(2.86)	14.02
BMYMP	1.10	0.24	0.09	0.29	1.04	(1.96)	3.40	(2.73)	12.65
META	1.39	(0.21)	0.00	(0.18)	0.00	0.00	2.30	(2.72)	13.52
AVGO	2.17	0.03	0.02	0.07	3.11	(2.07)	3.49	(4.48)	22.53

Unable to evaluate fundamental data of [NVDA, AAPL, GOOG, MSFT, AMZN, BMYMP, META, AVGO] at this time. Please try again later

All Fundamental Data

STRATEC Biomedical Competitive Analysis

The better you understand STRATEC Biomedical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, STRATEC Biomedical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across STRATEC Biomedical's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	SRBZF	NVDA	AAPL	GOOG	MSFT	AMZN	BMYMP	META	AVGO
	0.00 72.96 STRATEC	0.55 186.50 NVIDIA	0.33 270.95 Apple	0.00 313.80 Alphabet	2.28 472.61 Microsoft	1.91 226.40 Amazon	0.00 900.00 Bristol	1.46 650.42 Meta	0.44 347.62 Broadcom
Market Volatility (90 Days Market Risk)	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady
Market Performance (90 Days Performance)	Weakest	Weak	Fair	Good	Weakest	Soft	Good	Weakest	Weak
Odds of Financial Distress (Probability Of Bankruptcy)	Fair	Low	Tiny	Tiny	Low	Tiny	Low	Tiny	Low
Current Valuation (Equity Enterprise Value)	Fairly Valued	Under Valued	Over Valued	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Strong Buy	Buy	Strong Buy	Strong Buy	Strong Buy	Not Available	Strong Buy	Strong Buy
Trade Advice (90 Days Macroaxis Advice)	Hold	Sell	Strong Hold	Strong Buy	Hold	Hold	Strong Buy	Hold	Sell
Current Ratio	N/A	3.39	0.88	2.52	1.84	0.94	1.4	2.52	2.32
Net Asset	N/A	111.6 B	359.24 B	450.26 B	619 B	624.89 B	109.31 B	276.05 B	171.09 B
Profit Margin	N/A	0.53	0.27	0.32	0.36	0.11	N/A	0.31	0.36
EBITDA	N/A	86.14 B	144.43 B	135.39 B	160.16 B	123.81 B	20.1 B	86.88 B	34.71 B
Operating Margin	N/A	0.63	0.32	0.31	0.49	0.11	N/A	0.4	0.32
Current Valuation	N/A	4.48 T	4.06 T	3.72 T	3.55 T	2.51 T	N/A	1.69 T	1.69 T
Price To Book	N/A	38.12	54.48	9.79	9.9	6.68	N/A	8.65	20.19
Retained Earnings	N/A	68.04 B	(14.26 B)	245.08 B	237.73 B	172.87 B	N/A	102.51 B	9.76 B
Current Asset	N/A	6.05 B	106.87 B	105.41 B	139.66 B	35.7 B	N/A	N/A	7.12 B
Five Year Return	N/A	0.2	1.0	N/A	1.18	N/A	N/A	N/A	3.06
Beta	N/A	2.28	1.11	1.07	1.07	1.37	0.35	1.27	1.2
Number Of Employees	7	36 K	166 K	190.17 K	228 K	1.58 M	23.7 K	78.45 K	33 K
Shares Outstanding	N/A	24.3 B	14.78 B	5.41 B	7.43 B	10.69 B	N/A	2.18 B	4.74 B
Cash Flow From Operations	N/A	64.09 B	111.48 B	125.3 B	136.16 B	115.88 B	16.21 B	91.33 B	27.54 B
Annual Yield	N/A	2.0E-4	0.0038	0.0027	0.0075	N/A	0.0012	0.0032	0.0075
Total Debt	N/A	10.27 B	112.38 B	25.46 B	60.59 B	130.9 B	39.6 B	49.06 B	65.14 B
Return On Equity	N/A	1.07	1.71	0.35	0.32	0.24	N/A	0.33	0.31
Return On Asset	N/A	0.54	0.23	0.16	0.15	0.075	N/A	0.18	0.0979
Number Of Shares Shorted	N/A	264.29 M	122.04 M	56.15 M	66.68 M	76.07 M	N/A	31.95 M	69.79 M
Book Value Per Share	N/A	4.89	4.99	32.03	48.84	34.59	7.55	76.98	59.22
Current Liabilities	N/A	2.35 B	79.01 B	16.76 B	59.36 B	33.89 B	N/A	N/A	3.08 B
Total Asset	N/A	111.6 B	359.24 B	450.26 B	619 B	624.89 B	109.31 B	276.05 B	171.09 B
Debt To Equity	N/A	0.56	2.61	0.12	0.44	1.2	59.4	0.13	1.89
Short Ratio	N/A	1.28	2.83	1.9	2.65	1.76	N/A	1.8	2.18
Target Price	N/A	253.02	287.71	328.21	622.51	295.6	N/A	837.15	456.8
Last Dividend Paid	N/A	0.04	1.02	1.02	3.4	N/A	1.59	2.08	2.42
Shares Owned By Institutions	N/A	69.34	64.36	60.72	75.7	66.75	N/A	79.39	79.26
Market Capitalization	946.79 M	4.54 T	4.03 T	3.79 T	3.59 T	2.47 T	2.11 T	1.66 T	1.64 T
Price To Earning	N/A	41.94	24.24	20.62	26.64	83.26	N/A	9.3	22.94
Price To Earnings To Growth	N/A	0.71	2.75	1.66	1.98	1.56	N/A	1.57	0.97
Price To Sales	N/A	24.26	9.69	9.83	12.24	3.57	N/A	8.78	25.69
Net Income	N/A	72.88 B	112.01 B	100.12 B	101.83 B	59.25 B	7.01 B	62.36 B	23.13 B
Earnings Per Share	N/A	4.05	7.45	10.14	14.07	7.09	N/A	22.78	4.78
Shares Owned By Insiders	N/A	4.33	1.69	6.68	0.06	9.17	N/A	0.06	2.0
Revenue	N/A	130.5 B	416.16 B	350.02 B	281.72 B	637.96 B	46.38 B	164.5 B	63.89 B
Working Capital	N/A	62.08 B	(17.67 B)	74.59 B	49.91 B	11.44 B	N/A	66.45 B	13.06 B
Cash And Equivalents	N/A	13.14 B	7.67 B	116.26 B	30.24 B	78.78 B	6.07 B	40.49 B	9.98 B
Cash Per Share	N/A	5.34	3.04	8.98	14.39	5.75	3.72	15.06	24.63
Gross Profit	67.5 M	131.09 B	195.2 B	228.1 B	202.04 B	345.98 B	N/A	155.38 B	49.4 B
Day Typical Price	72.96	187.85	271.86	313.8	477.79	228.6	900.0	655.28	347.64
Accumulation Distribution	N/A	0.0214	0.01	0.0101	0.0318	0.0283	N/A	0.0219	0.0127
Market Facilitation Index	N/A	4.07	2.73	3.19	15.53	6.59	N/A	14.58	4.46
Daily Balance Of Power	0.0	(0.26)	(0.33)	N/A	(0.71)	(0.67)	0.0	(0.66)	0.3408
Period Momentum Indicator	N/A	(1.04)	(0.91)	N/A	(11.01)	(4.42)	N/A	(9.67)	1.52
Rate Of Daily Change	1.0	0.99	1.0	1.0	0.98	0.98	1.0	0.99	1.0
Day Median Price	72.96	188.53	272.32	313.79	480.38	229.7	900.0	657.71	347.65
Price Action Indicator	N/A	(2.55)	(1.82)	0.005	(13.27)	(5.50)	N/A	(12.13)	0.73
Coefficient Of Variation	N/A	3566.45	1002.11	455.87	(1,385)	2609.05	615.13	(1,325)	2366.73
Mean Deviation	N/A	1.82	0.738	1.4	0.8877	1.38	1.1	1.39	2.17
Jensen Alpha	N/A	0.0084	0.0554	0.3377	(0.12)	0.0043	0.2362	(0.21)	0.0327
Total Risk Alpha	N/A	(0.10)	0.0234	0.2621	(0.17)	(0.07)	0.1599	(0.31)	(0.1)
Sortino Ratio	N/A	0.0024	0.0463	0.2291	N/A	0.0095	0.0945	N/A	0.0225
Downside Variance	N/A	5.23	1.12	2.18	N/A	4.13	6.24	N/A	11.66
Standard Deviation	N/A	2.29	1.08	1.81	1.17	2.03	1.81	2.08	3.2
Kurtosis	N/A	(0.20)	3.09	0.6169	0.0982	6.76	4.61	12.05	4.29
Potential Upside	N/A	3.01	1.97	3.33	1.78	2.53	3.4	2.3	3.49
Treynor Ratio	N/A	0.0575	0.1124	0.384	(0.16)	0.0518	0.2856	(0.18)	0.0657
Maximum Drawdown	N/A	9.61	5.76	9.42	5.08	14.02	12.65	13.52	22.53
Variance	N/A	5.23	1.16	3.27	1.37	4.14	3.29	4.31	10.25
Market Risk Adjusted Performance	N/A	0.0675	0.1224	0.394	(0.15)	0.0618	0.2956	(0.17)	0.0757
Risk Adjusted Performance	N/A	0.0267	0.0739	0.1609	(0.05)	0.0336	0.1208	(0.05)	0.0376
Skewness	N/A	(0.05)	0.2906	0.518	(0.48)	1.19	0.8007	(2.30)	0.0815
Semi Deviation	N/A	2.2	0.8986	1.14	N/A	1.87	1.04	N/A	3.11
Information Ratio	N/A	0.0024	0.0455	0.187	(0.12)	0.0095	0.1302	(0.10)	0.024
Value At Risk	N/A	(3.81)	(1.56)	(2.27)	(2.50)	(2.86)	(2.73)	(2.72)	(4.48)
Expected Short fall	N/A	(1.94)	(0.76)	(1.64)	N/A	(1.27)	(1.96)	N/A	(2.07)
Downside Deviation	N/A	2.29	1.06	1.48	N/A	2.03	2.5	N/A	3.42
Semi Variance	N/A	4.86	0.8074	1.3	N/A	3.5	1.07	N/A	9.7

STRATEC Biomedical Competition Performance Charts

Five steps to successful analysis of STRATEC Biomedical Competition

STRATEC Biomedical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by STRATEC Biomedical in relation to its competition. STRATEC Biomedical's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of STRATEC Biomedical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact STRATEC Biomedical's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to STRATEC Biomedical, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your STRATEC Biomedical position

In addition to having STRATEC Biomedical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Junk Bonds Funds Thematic Idea Now

Junk Bonds Funds

Funds or Etfs that invest most of their assets into speculative (junk) bonds or to other fixed income instruments with interest rates 3 to 4 percentage points above government issues. The Junk Bonds Funds theme has 46 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Junk Bonds Funds Theme or any other thematic opportunities.

View All Next

Launch

Other Information on Investing in STRATEC Pink Sheet

STRATEC Biomedical financial ratios help investors to determine whether STRATEC Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in STRATEC with respect to the benefits of owning STRATEC Biomedical security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

STRATEC Competitors

Specify up to 10 symbols:

STRATEC Biomedical Competition Correlation Matrix

High positive correlations

High negative correlations

Risk-Adjusted Indicators

STRATEC Biomedical Competitive Analysis

STRATEC Biomedical Competition Performance Charts

Five steps to successful analysis of STRATEC Biomedical Competition

Complement your STRATEC Biomedical position

Did You Try This Idea?

Run Junk Bonds Funds Thematic Idea Now

Junk Bonds Funds

Other Information on Investing in STRATEC Pink Sheet

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY